Discontinued — last reported Q3 '25
Royalty Pharma Distributions from equity method investments decreased by 72.2% to $3.72M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 72.2%, from $13.40M to $3.72M. Over 2 years (FY 2021 to FY 2023), Distributions from equity method investments shows a downward trend with a -26.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase signals successful capital allocation and returns from strategic partnerships.
Cash received from unconsolidated affiliates or entities accounted for under the equity method. This represents actual c...
Common for holding companies with diverse investment portfolios.
distributions_from_equity_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.68M | $6.21M | $6.17M | $20.69M | $6.81M | $5.81M | $5.83M | $16.27M | $2.24M | $313.00K | $0.00 | $13.40M | $13.40M | $3.72M |
| QoQ Change | — | +32.7% | -0.6% | +235.3% | -67.1% | -14.7% | +0.2% | +179.2% | -86.2% | -86.0% | -100.0% | — | +0.0% | -72.2% |
| YoY Change | — | — | — | — | +45.6% | -6.4% | -5.6% | -21.4% | -67.1% | -94.6% | -100.0% | -17.6% | +0.0% | -72.2% |